Meriofert Pfs (Luteinising Hormone (Human), Follicle-Stimulating Hormone)

Meriofert Pfs, a gonadotropin preparation, is used in reproductive endocrinology to stimulate ovarian or testicular function.

• Infertility due to anovulation or oligospermia: enhances follicular development in women and spermatogenesis in men to improve chances of conception.
• Controlled ovarian hyperstimulation for assisted reproductive technology: induces development of multiple follicles to enable egg retrieval for IVF or ICSI cycles.
• Hypogonadotropic hypogonadism: replaces deficient LH and FSH to initiate puberty or maintain fertility in patients with pituitary or hypothalamic disorders.

• Meriofert Pfs contains recombinant human luteinising hormone and follicle‑stimulating hormone that bind to LH and FSH receptors on gonadal cells. Activation of these G‑protein‑coupled receptors stimulates adenylate cyclase, increasing cAMP production, which drives steroidogenesis and gametogenesis. The combined action promotes follicular maturation, ovulation, and testosterone synthesis, thereby restoring normal reproductive hormone cascades. The synergistic effect supports the endocrine feedback loop essential for normal menstrual cycles and spermatogenic processes.

Adverse reactions to Meriofert Pfs are generally related to its hormonal activity and the injection route.

Common Side Effects

• Injection site pain or erythema: mild discomfort or redness at the site of administration.
• Headache: transient tension‑type headache occurring after dosing.
• Nausea or abdominal discomfort: mild gastrointestinal upset that resolves spontaneously.
• Mild ovarian hyperstimulation: excessive follicular response without severe complications.

Serious or Rare Side Effects

• Severe ovarian hyperstimulation syndrome: rapid weight gain, ascites, or respiratory distress requiring medical attention.
• Thromboembolic events: deep vein thrombosis or pulmonary embolism in predisposed individuals.
• Allergic reactions: urticaria, angioedema, or anaphylaxis following injection.

When using Meriofert Pfs, clinicians should consider several precautionary measures to minimise risk.

• Pregnancy: avoid use unless specifically indicated and supervised by a fertility specialist.
• Breastfeeding: exercise caution as hormonal effects on lactation are not fully established.
• Ovarian hyperstimulation syndrome: monitor patients closely for signs of excessive response.
• Thromboembolic risk: assess personal or family history of clotting disorders before treatment.
• Allergy: do not administer to patients with known hypersensitivity to human LH or FSH preparations.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert Pfs may interact with other medicines that influence hormonal pathways or coagulation.

Major Interactions (Avoid)

• GnRH analogues: concurrent use can blunt the intended gonadotropin response.
• Estrogen‑containing oral contraceptives: suppress endogenous LH/FSH and reduce efficacy of therapy.

Moderate Interactions (Monitor Closely)

• Anticoagulants: increased risk of thrombosis when ovarian hyperstimulation occurs; monitor coagulation parameters.
• Thyroid hormone therapy: gonadotropins can affect thyroid function tests; periodic monitoring is advised.
• Diuretics: may alter fluid balance and affect injection site reactions; observe patient tolerance.